TROPION-Breast01 最终总生存分析:Dato-DXd 对比化疗
TROPION-Breast01 研究比较 Dato-DXd 与研究者选择化疗用于经治的不可手术/转移性 HR 阳性/HER2 阴性乳腺癌,最终总生存分析显示两组 OS 无统计学显著差异(HR 1.01,95%CI 0.83-1.22,P=0.9445),后续 ADC 治疗在两组间分布不均衡可能影响 OS 结果;PFS 等次要终点仍倾向 Dato-DXd,安全性可控。
要点
- Dato-DXd 对比 ICC 的 OS 无显著差异(HR 1.01,95%CI 0.83-1.22,P=0.9445)。
- 后续 ADC 治疗比例不均衡:Dato-DXd 组 12.3% vs ICC 组 24.0%。
- PFS 等次要疗效终点在最终分析中仍倾向 Dato-DXd,安全性未出现新信号。
核心结论
- TROPION-Breast01 达到 BICR 评估 PFS 的双主要终点,但 Dato-DXd 对比 ICC 的 OS 未达统计学显著改善。
研究设计与样本
- III 期随机对照研究,不可手术/转移性 HR 阳性/HER2 阴性乳腺癌患者按 1:1 随机接受 Dato-DXd(6 mg/kg 每 3 周)或 ICC(艾立布林/卡培他滨/长春瑞滨/吉西他滨)。
- 入组条件为内分泌治疗进展且不适合内分泌治疗、不可手术/转移性阶段接受过 1–2 线化疗。
- 双主要终点为 BICR 评估 PFS 和 OS,本次报告最终 OS 分析。
主要发现
- 数据截止时中位随访 22.8 个月,Dato-DXd 对比 ICC 的 OS 无统计学显著性(HR 1.01,95%CI 0.83-1.22,P=0.9445)。
- 后续 ADC 治疗(T-DXd 和 SG)使用不均衡:Dato-DXd 组 12.3% vs ICC 组 24.0%。
- 次要疗效终点(研究者评估 PFS、ORR、DoR、12 周 DCR、至首次/第二次后续治疗或死亡时间、至第二次进展或死亡时间)在最终分析中仍倾向 Dato-DXd。
- Dato-DXd 总体安全性相较 ICC 仍有利,延长随访未观察到新安全性信号。
临床怎么用
- 对于经治的不可手术/转移性 HR 阳性/HER2 阴性乳腺癌,Dato-DXd 可作为新的治疗选择,但需结合后续 ADC 可及性综合考量。
局限性
- 后续 ADC 治疗在两组间使用不均衡(Dato-DXd 组 12.3% vs ICC 组 24.0%),可能影响 OS 结果解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The TROPION-Breast01 study (NCT05104866) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) by blinded independent central review (BICR) with the trophoblast cell-surface antigen 2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) versus investigator's choice of chemotherapy (ICC) in patients with previously treated, inoperable/metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. In this article, we report results from the final overall survival (OS) analysis. PATIENTS AND METHODS: Patients with inoperable/metastatic HR-positive/HER2-negative breast cancer, who had disease progression on endocrine therapy and for whom endocrine therapy was unsuitable, and had received one to two prior lines of chemotherapy in the inoperable/metastatic setting were randomly assigned in a 1 : 1 ratio to Dato-DXd (6 mg/kg every 3 weeks) or ICC (eribulin/capecitabine/vinorelbine/gemcitabine). Dual primary endpoints were PFS by BICR and OS. RESULTS: At data cut-off, median follow-up was 22.8 months. OS for the Dato-DXd versus ICC arm did not reach statistical significance (hazard ratio 1.01, 95% confidence interval 0.83-1.22, P = 0.9445). Use of ADCs (trastuzumab deruxtecan and sacituzumab govitecan) as subsequent therapy was imbalanced: 12.3% in the Dato-DXd arm versus 24.0% in the ICC arm. Secondary efficacy endpoints (PFS by investigator assessment, objective response rate, duration of response, disease control rate at 12 weeks, time to first and second subsequent therapy or death, and time to second progression or death) continued to favor Dato-DXd at this final analysis. The overall safety profile of Dato-DXd remained favorable compared with ICC, and no new safety signals were observed with longer follow-up. CONCLUSIONS: TROPION-Breast01 met its dual primary endpoint of PFS by BICR. While there was no statistically significant improvement in the dual primary endpoint of OS with Dato-DXd versus ICC, subsequent ADC treatment may have affected OS results. The totality of efficacy and safety data supports Dato-DXd as a new treatment option for patients with previously treated, inoperable/metastatic HR-positive/HER2-negative breast cancer.
引用
- Pistilli B, Jhaveri K, Im SA, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study. Ann Oncol. 2025. PMID: 41448362. doi:10.1016/j.annonc.2025.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。